Biocompatible WSe2@BSA Dots with Merged Catalyst and Coreactant for Efficient Electrochemiluminescence

Abstract Electrochemiluminescence (ECL) is a powerful tool for clinical diagnosis due to its exceptional sensitivity. However, the standard tripropylamine (TPrA) coreactant for Ru(bpy) 3 Cl 2 , the most widely studied and used ECL system, is highly toxic. Despite extensive research on alternative coreactants, they often fall short in poor efficiency. From a reaction kinetics perspective, accelerating electrooxidation rate of Ru(bpy) 3 Cl 2 is an essential way to compensate the efficiency limitation of coreactants, but is rarely reported. Here, a hybrid electrocatalyst@coreactant dots for the ECL of Ru(bpy) 3 Cl 2 is reported. The as‐prepared WSe 2 @bovine serum albumin (WSe 2 @BSA) dots is biocompatible, and demonstrate dual functions, i.e., the BSA shell works as a coreactant, meanwhile, the WSe 2 core effectively catalyzes Ru(bpy) 3 Cl 2 oxidation. As a result, WSe 2 @BSA dots exhibit an exceptionally high efficiency comparable to TPrA for the ECL of Ru(bpy) 3 Cl 2 . In addition, the procedure for synthesizing WSe 2 @BSA dots is facile (room temperature, atmospheric conditions), rapid (5 min), and scalable (for millions of bioassays). A biosensor utilizing WSe 2 @BSA dots shows promise for highly sensitive detecting glypican‐3 in clinical liver cancer serum samples, especially for alpha‐fetoprotein‐negative patients. This work opens a new avenue for developing a highly efficient ECL system for biosensing and clinical diagnosis.